Ambu A/S vs NovoCure Limited
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Ambu A/S is the larger company by market value: $3.2 B against $1.5 B for NovoCure Limited, 2.1 times as much (market caps of Aug 1, 2026 for Ambu A/S and Oct 30, 2026 for NovoCure Limited). Ambu A/S's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
- Ambu A/S had more revenue: $657 M in the year to September 2022 against $655 M for NovoCure Limited in the year to December 2025.
- Ambu A/S made a net profit of $14 M, while NovoCure Limited made a net loss of $136 M.
- Ambu A/S keeps more of each dollar of sales: a net margin of 2.1% against -20.8% for NovoCure Limited.
- Ambu A/S employs more people: 3,500 against 1,023 at NovoCure Limited. Each employee brings in about $187,714 of revenue at Ambu A/S and $640,616 at NovoCure Limited.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Ambu A/S AMBU-B.CO · #4,870 in the world | NovoCure Limited NVCR · #7,428 in the world |
|---|---|---|
| Profile | ||
| Country | 🇩🇰 Denmark | 🇬🇧 UK |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments | Medical Instruments |
| Founded | 1937 | 2000 |
| Size | ||
| Market cap | $3.2 B | $1.5 B |
| Revenue | $657 M | $655 M |
| Net income | $14 M▲ best | $-136 M |
| Employees | 3,500 | 1,023 |
| Valuation | ||
| P/E ratio | 226× | — |
| Price to sales | 4.8× | 2.1× |
| Price to book | 3.4× | 4.5× |
| Free cash flow yield | — | -4.9% |
| Profitability | ||
| Gross margin | — | 74.5% |
| Operating margin | — | -23.5% |
| Net margin | — | -20.8% |
| Return on equity | — | -38.9% |
| Growth | ||
| Revenue growth | — | 8.3% |
| Revenue growth, 3 years a year | — | 6.8% |
| Financial strength | ||
| Debt to equity | — | 0.6× |
| Interest cover | — | -6.9× |
| Cash | ||
| Free cash flow margin | — | -11.6% |
| Strength scores | ||
| Piotroski F-score | — | 3 of 9 |
| Altman Z-score zone | — | distress |
| Data as of | Market cap Aug 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Ambu A/S or NovoCure Limited?
Ambu A/S is the larger company by market value: $3.2 B against $1.5 B for NovoCure Limited, 2.1 times as much (market caps of Aug 1, 2026 for Ambu A/S and Oct 30, 2026 for NovoCure Limited). Ambu A/S's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
Which makes more money, Ambu A/S or NovoCure Limited?
Ambu A/S had more revenue: $657 M in the year to September 2022 against $655 M for NovoCure Limited in the year to December 2025. Ambu A/S made a net profit of $14 M, while NovoCure Limited made a net loss of $136 M.
Which is more profitable, Ambu A/S or NovoCure Limited?
Ambu A/S keeps more of each dollar of sales: a net margin of 2.1% against -20.8% for NovoCure Limited.
Which has more employees, Ambu A/S or NovoCure Limited?
Ambu A/S employs more people: 3,500 against 1,023 at NovoCure Limited. Each employee brings in about $187,714 of revenue at Ambu A/S and $640,616 at NovoCure Limited.
More about Ambu A/S
More about NovoCure Limited
Sources#
Every figure on this page comes from these, with the date shown next to it.